<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">METHYLTESTOSTERONE</span><br/>(meth-ill-tess-toss'te-rone)<br/><span class="topboxtradename">Android, </span><span class="topboxtradename">Metandren <img border="0" src="../images/maple.gif"/>, </span><span class="topboxtradename">Testred, </span><span class="topboxtradename">Virilon<br/></span><b>Classifications:</b> <span class="classification">hormones and synthetic substitutes</span>; <span class="classification">androgen/anabolic steroid</span><br/><b>Prototype: </b>Testosterone<br/><b>Pregnancy Category: </b>X<br/><b>Controlled Substance: </b>Schedule III<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 25 mg tablets; 10 mg buccal tablet</p>
<h1><a name="action">Actions</a></h1>
<p>Short-acting steroid with androgen/anabolic activity ratio (1:1) similar to that of testosterone but less effective than its
         esters. Fails to produce full sexual maturation when administered to preadolescent male with complete testicular failure unless
         preceded by testosterone therapy.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Androgen activity is similar to testosterone; used in replacement therapy, and palliative treatment of postmenopausal female
         breast cancer.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Androgen replacement therapy, delayed puberty (male), palliation of female mammary cancer (15 y postmenopausal), postpartum
         breast engorgement.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Liver dysfunction; prostate cancer; pregnancy (category X), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Liver, kidney, or cardiac dysfunction.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Replacement</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1050 mg/d in divided doses<br/><br/><span class="indicationtitle">Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 50200 mg/d in divided doses for duration of therapeutic response or no longer than 3 mo if no remission<br/><br/><span class="indicationtitle">Postpartum Breast Engorgement</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 80 mg/d for 35 d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Place buccal tablets between cheek and gum. Ensure that tablet is absorbed, not chewed or swallowed; and eating or drinking
            avoided until absorption is complete.
         </li>
<li>Store at 15°30° C (59°86° F). Avoid freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> <span class="speceff-life">Cholestatic hepatitis with jaundice</span>, irritation of oral mucosa with buccal administration. <span class="typehead">Urogenital:</span> Renal calculi (especially in immobilized patient), priapism. <span class="typehead">Endocrine:</span> <span class="speceff-common">Acne, gynecomastia, edema,</span> oligospermia, menstrual irregularities. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> Increases risk of bleeding associated with <span class="classification">oral anticoagulants</span>; possibly increases risk of <b>cyclosporine</b> toxicity; may decrease glucose level, making adjustment of doses of <b>insulin,</b> <span class="classification">sulfonylureas</span> necessary. <span class="typehead">Herbal:</span> <b>Echinacea</b> may increase risk of hepatotoxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor liver function periodically; report signs of hepatic toxicity (see Appendix F).</li>
<li>Monitor for flank pain, abdominal pain radiating to groin, or other symptoms of renal calculi.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be prepared for distressing and undesirable adverse effects of virilization (women) since dosage sufficient to produce remission
            in breast cancer is quantitatively similar to that used for androgen replacement in the male.
         </li>
<li>Report signs of virilism promptly. Voice change and hirsutism may be irreversible, even after drug is withdrawn.</li>
<li>Report priapism (men) or other signs of excess sexual stimulation. The physician will terminate therapy.</li>
<li>Report symptoms of jaundice with or without pruritus to physician; appears to be dose related. If liver function tests are
            altered at the same time, this drug will be withdrawn.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>